Tremfya Union européenne - finnois - EMA (European Medicines Agency)

tremfya

janssen-cilag international nv - guselkumab - psoriasis - immunosuppressantit - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.

Erleada Union européenne - finnois - EMA (European Medicines Agency)

erleada

janssen-cilag international nv - apalutamide - prostatiset kasvaimet - endokriinihoito - erleada on tarkoitettu:aikuisten miesten hoitoon ei metastasoitunutta kastraation kastraatioresistentin eturauhassyövän (nmcrpc), joilla on suuri riski sairastua etäpesäkkeitä. aikuisten miesten ei-metastasoituneen hormoni-herkkä eturauhasen syöpä (mhspc) yhdessä androgeenideprivaatiohoito (adt).

Spravato Union européenne - finnois - EMA (European Medicines Agency)

spravato

janssen-cilag international nv - esketamine hydrochloride - masennustila - muita masennuslääkkeitä - spravato, yhdessä ssri tai snri, on tarkoitettu aikuisille, joilla hoitoresistenttiin masennus, jotka eivät ole vastanneet vähintään kaksi eri hoitoja masennuslääkkeet nykyisessä kohtalainen tai vakava masennustila.

Zabdeno Union européenne - finnois - EMA (European Medicines Agency)

zabdeno

janssen-cilag international n.v.    - recombinant adenovirus type 26 (ad26) encoding the glycoprotein (gp) of the ebola virus zaire (zebov) mayinga strain - verenvuotokuume ebola - rokotteet - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Mvabea Union européenne - finnois - EMA (European Medicines Agency)

mvabea

janssen-cilag international n.v.    - recombinant modified vaccinia ankara bavarian nordic virus encoding the: ebola virus zaire (zebov) mayinga strain glycoprotein (gp); ebola virus sudan gulu strain gp; ebola virus taï forest strain nucleoprotein and the marburg virus musoke strain gp - verenvuotokuume ebola - rokotteet - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Jcovden (previously COVID-19 Vaccine Janssen) Union européenne - finnois - EMA (European Medicines Agency)

jcovden (previously covid-19 vaccine janssen)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - rokotteet - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. käyttö tämä rokote tulee virallisten suositusten mukaisesti.

Rybrevant Union européenne - finnois - EMA (European Medicines Agency)

rybrevant

janssen-cilag international n.v.    - amivantamab - karsinooma, ei-pienisoluinen keuhko - antineoplastiset aineet - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Carvykti Union européenne - finnois - EMA (European Medicines Agency)

carvykti

janssen-cilag international nv - ciltacabtagene autoleucel - multiple myeloma - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Tecvayli Union européenne - finnois - EMA (European Medicines Agency)

tecvayli

janssen-cilag international n.v. - teclistamab - multiple myeloma - antineoplastiset aineet - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Akeega Union européenne - finnois - EMA (European Medicines Agency)

akeega

janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - eturauhasen kasvaimet, kastraatio-resistentin - antineoplastiset aineet - treatment of adult patients with prostate cancer.